Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bayer HealthCare AG
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Effect of exercise alone or in combination with testosterone replacement on muscle strength and quality of life in older men with low testosterone concentrations: a randomized double-blind, placebo controlled study
Additional effect of TRT in hypogonadal men on dynamic maximum strength (one repetition maximum, 1-RM) of upper and lower extremity
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A study to investigate the safety and tolerability of a 14 day oral treatment with different doses of BAY 1142524 in comparison to placebo in patients with left-ventricular dysfunction after myocardial infarction
The primary objective of this pilot study is to investigate the safety and tolerability after multiple oral doses of BAY 1142524 administered BID (using 3 dose groups) or OD (using a 4th dose group) a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Efficacy and safety of a progestin and an aromatase inhibitor combined in a intravaginal ring in symptomatic endometriosis
To assess the dose-response relationship and demonstrate efficacy of BAY 98-7196 vs. placebo in women with symptomatic endometriosis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Radium-223 Chloride in the treatment patients diagnosed with prostate cancer that has spread to the bone Cloruro de radio-223 en el tratamiento de pacientes con diagnóstico de cáncer de próstata que se ha extendido a los huesos
Provide radium-223 chloride to patients diagnosed with CRPC/HRPC with bone metastasis To assess acute and long-term safety of radium-223 chloride Administrar cloruro de radio-223 a pacientes a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)
The primary efficacy objectives of this study are to demonstrate that sensitivity and specificity of gadobutrol-enhanced CMRI exceed pre-specified minimum performance thresholds (MPT) of 60 and 55%, r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment versus 300 mg Aspirin® N tablets p.o. (BAY e4465A) in patients with Acute Coronary Syndrome, measured by time dependent thromboxane inhibition
To demonstrate superiority of 500 mg and 250 mg Aspirin® i.v. (BAY 81-8781) treatment over oral treatment with 300 mg Aspirin® N tablets to inhibit thromboxane A2-release (measured as stable metaboli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 80876395) in a 21-day regimen as compared to a monophasic contraceptive containing ethinyestradiol and levonogestrel (0.33 mg/0.15 mg) in a 21-day regimen on hemostatic parameters in 30 women aged 18-35 years over 3 treatment cycles in each period
To investigate the impact of the transdermal contraceptive patch in a 21-day regimen on hemostasis parameters in comparison to a combined oral contracetive in a 21-day regimen.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Evaluation of a Treat and Extend regimen of intravitreal aflibercept for macular edema secondary to CRVO
To determine the efficacy and durability (treatment interval) of 2 mg IVT aflibercept in a T&E regimen over a treatment period of 76 weeks using protocol defined visual and anatomic criteria in subjec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose- Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients with Essential Hypertension
To determine the dose-response of the various combinations of nifedipine GITS (gastrointestinal therapeutic system) and candesartan as compared to monotherapy and placebo based on the blood pressure (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen compared to ethinylestradiol / desogestrel (0.02 mg/0.15 mg) oral contraception in a 21/7 regimen on hormone withdrawal associated symptoms in otherwise healthy women after 4 cycles of treatment
To show superiority of 24/4 OC to 21/7 OC with regard to changes in frequency and intensity of hormone withdrawal associated symptoms on cycle days 22 – 28 from baseline to cycle 4 in approximately 55...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant